<SEC-DOCUMENT>0001104659-22-062690.txt : 20220519
<SEC-HEADER>0001104659-22-062690.hdr.sgml : 20220519
<ACCEPTANCE-DATETIME>20220519062716
ACCESSION NUMBER:		0001104659-22-062690
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20220519
FILED AS OF DATE:		20220519
DATE AS OF CHANGE:		20220519

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prenetics Global Ltd
		CENTRAL INDEX KEY:			0001876431
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41401
		FILM NUMBER:		22941111

	BUSINESS ADDRESS:	
		STREET 1:		7/F, K11 ATELIER, 728 KING'S ROAD
		CITY:			QUARRY BAY
		STATE:			K3
		ZIP:			000000
		BUSINESS PHONE:		(852) 2210-7188

	MAIL ADDRESS:	
		STREET 1:		7/F, K11 ATELIER, 728 KING'S ROAD
		CITY:			QUARRY BAY
		STATE:			K3
		ZIP:			000000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2127588d71_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE<BR>
13a-16 OR 15d-16 UNDER<BR>
THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the month of May 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number 001-41401 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prenetics Global Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Unit 701-706, K11 Atelier King&#8217;s Road</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>728 King&#8217;s Road, Quarry Bay</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Hong Kong</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.&nbsp; Form&nbsp;20-F&nbsp; <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT> Form&nbsp;40-F&nbsp;
<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K
in paper as permitted by Regulation S-T&nbsp;Rule&nbsp;101(b)(1): <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K
in paper as permitted by Regulation S-T&nbsp;Rule&nbsp;101(b)(7): <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Closing of the Business
Combination and Nasdaq Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">On May&nbsp;18, 2022,
Prenetics Global Limited (&#8220;PubCo&#8221;) issued a press release announcing the closing of the business combination contemplated
by the Business Combination Agreement, dated as of September 15, 2021, as amended by an Amendment to Business Combination Agreement dated
as of March 30, 2022, by and among PubCo, Artisan, AAC Merger Limited, PGL Merger Limited and Prenetics Holding Limited (formerly known
as Prenetics Group Limited), and the listing of PubCo&#8217;s Class&nbsp;A ordinary shares and warrants on The Nasdaq Stock Market LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">The press release is
furnished as Exhibit 99.1 to this Report on Form&nbsp;6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Exhibit Index</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 59.05pt; text-indent: -59.05pt"><A HREF="tm2127588d71_ex99-1.htm" STYLE="-sec-extract: exhibit">Exhibit 99.1&#8212;Press Release</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 59.05pt; text-indent: -59.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>Prenetics Global Limited</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 50%">&nbsp;</TD>
<TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
<TD STYLE="width: 45%; border-bottom: black 1pt solid">/s/ <FONT STYLE="font-size: 10pt">Stephen&nbsp;Lo</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">Stephen&nbsp;Lo</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
<TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 10pt">Date: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;May 19, 2022</FONT></TD>
<TD COLSPAN="2">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2127588d71_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><IMG SRC="tm2127588d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prenetics Rings the Opening Bell and Debuts
on Nasdaq</B></P>

<DIV STYLE="float: left; width: 68%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 1pt; width: 0.25in; padding-bottom: 1pt"></TD><TD STYLE="padding-top: 1pt; width: 0.25in; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 1pt; text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prenetics becomes the first Hong Kong unicorn
to list on Nasdaq and its shares began trading on May 18 under ticker &ldquo;PRE&rdquo;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-top: 1pt; width: 0.25in; padding-bottom: 1pt"></TD><TD STYLE="padding-top: 1pt; width: 0.25in; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 1pt; text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">At Least&nbsp;US$260M&nbsp;of Proceeds from the
Business Combination, Cash and Trade Receivables to Support Prenetics Growth</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-top: 1pt; width: 0.25in; padding-bottom: 1pt"></TD><TD STYLE="padding-top: 1pt; width: 0.25in; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-top: 1pt; text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
will allow Prenetics to continue its significant growth trajectory and will be used for strategic acquisitions, R&amp;D, product rollout
and geographic expansion into EMEA and Southeast Asia</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>LONDON and HONG KONG, May 18, 2022</B>
(GLOBE NEWSWIRE) &ndash; Prenetics Group Limited (&quot;Prenetics&quot; or the &quot;Company&quot;), a global leader in genomic and
diagnostic testing, and Artisan Acquisition Corp. (Nasdaq: ARTAU, &quot;Artisan&quot;), a special purpose acquisition company
privately founded by renowned cultural entrepreneur Adrian Cheng, today completed their previously announced business combination.
The combined company started trading on Nasdaq on May 18, 2022 under the new ticker symbols &quot;PRE&quot; for Prenetics class A
ordinary shares and &ldquo;PRENW&rdquo; for Prenetics warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Artisan shareholders approved the business combination
at the Extraordinary General Meeting on May 9, 2022. Danny Yeung, Chief Executive Officer and Co-Founder of Prenetics, will continue to
lead the combined company. Adrian Cheng, Founder of Artisan, will remain a strategic shareholder and Ben Cheng, CEO of Artisan, is now
a board member of Prenetics. The transaction values Prenetics at an enterprise value of US$1.25 billion, making the Company the first
Hong Kong unicorn to list on the Nasdaq.</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<DIV STYLE="float: right; width: 30%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Prenetics Rings the Opening Bell and Debuts
on Nasdaq</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm2127588d1_ex99-1img003.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adrian Cheng and Danny Yeung ring the Nasdaq Opening Bell</P>

</DIV>

<DIV STYLE="clear: both; width: 100%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Danny Yeung, Chief Executive Officer and Co-Founder
of Prenetics</B>, said, &ldquo;Today marks an incredible milestone for Prenetics and it would not have been possible without our amazing
team. I like to thank Adrian Cheng and the entire Artisan team for their trust and their un-wavering support. While we have accomplished
a lot since our founding in 2014, I feel we are only getting started. Our vision is to create a full end to end health ecosystem consisting
of prevention, diagnostics and personalized care to millions of people around the World. As a Nasdaq listed company, we can&rsquo;t be
more excited and confident in our future, and believe that shareholders will benefit from our ambition, drive and ability to execute .&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Adrian Cheng, Founder of Artisan</B>, said,
 &ldquo;For Prenetics to become the first Hong Kong unicorn to list on the Nasdaq is a significant achievement and I thank everyone involved.
It was my core mission to seek out a high growth company with potential to make a meaningful impact on the healthcare industry globally
and I&rsquo;m very pleased it was Prenetics. This is an important milestone not only for Prenetics, but for all next generation entrepreneurs
in Hong Kong. Danny has truly built an amazing company and I&rsquo;m confident in its long-term strategy of creating a full end to end
healthcare ecosystem&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The company is going public in the wake of seeing
robust momentum across its testing services, making it one of the fastest growing genomic and diagnostic testing companies going public
this year. Below are some key highlights:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Strong financial growth with ample cash on balance sheet </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prenetics&rsquo; FY2021 revenue reached US$275.9 million, up 323% year-on-year,
exceeding its previous financial projection of US$205 million for the year</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Q1 2022 revenue reached a record high of US$92.0
million, an increase of 60.2% y-o-y</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As of March 31, 2022, the Company had cash and trade receivables of US$93.4
million, consisting of US$34.2 million of cash and US$59.2 million of trade receivables</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Sustained growth momentum with global M&amp;A strategy and geographic
expansion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Advanced M&amp;A discussions with multiple companies in Europe and Southeast
Asia in the areas of telehealth and personalized care, which will add additional revenues and new technology </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Launching new pipeline products into our existing markets and entering into
new geographies including Europe and Southeast Asia through organic and inorganic growths</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2127588d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Building the future of healthcare; Prenetics aims to a healthcare
ecosystem with strong technological and commercial synergies through its existing and pipeline products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Processed and delivered more than 22 million COVID-19 laboratory and rapid
at-home tests globally to date, with blue chip clientele of governments and multinational corporates</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Over 140,000 Circle DNA tests, a clinical-grade consumer testing utilizing
whole exome sequencing, have been delivered to over 30 countries to date </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Circle ColoClear - Non-invasive stool-based FIT-DNA test for colorectal cancer
screening. To be launched in the first half of 2022</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Circle SnapShot - At-home blood test with a user-friendly blood sample collection
and result delivery system. To be launched in the first half of 2022</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">UBS Securities LLC is acting as sole financial
advisor and exclusive capital markets advisor to Artisan. Citigroup Global Markets Asia Limited is acting as sole financial advisor to
Prenetics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">UBS Securities LLC, Citigroup Global Markets Inc.,
Credit Suisse Securities (USA) LLC and China International Capital Corporation Hong Kong Securities Limited are serving as placement agents
on the PIPE. Skadden, Arps, Slate, Meagher &amp; Flom LLP is serving as international legal counsel, and Mourant is serving as Cayman
legal counsel, to Prenetics. Kirkland &amp; Ellis LLP is serving as international legal counsel, and Appleby is serving as Cayman legal
counsel, to Artisan. Shearman &amp; Sterling LLP is serving as international legal counsel to the placement agents. KPMG LLP is serving
as the auditor to Prenetics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Prenetics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Founded in 2014, Prenetics is a major global
diagnostics and genetic testing company with the mission to bring health closer to millions of people globally and decentralize healthcare
by making the three pillars &mdash; Prevention, Diagnostics and Personalized Care &mdash; comprehensive and accessible to anyone, at
anytime and anywhere. Prenetics is led by visionary entrepreneur, Danny Yeung, with operations across 9 locations, including United Kingdom,
Hong Kong, India, South Africa, and Southeast Asia. Prenetics develops consumer genetic testing and early colorectal cancer screening;
provides COVID-19 testing, rapid point of care and at-home diagnostic testing and medical genetic testing. To learn more about Prenetics,
visit <U>www.prenetics.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Artisan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Artisan is a special purpose acquisition company
incorporated in the Cayman Islands for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization
or similar business combination with one or more businesses or entities. The company searches globally for a target with operations or
prospects focusing on high-growth healthcare, consumer and technology sectors, and companies that it believes can be well-positioned for
success in Greater China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Investors:<BR>
</I></B>Sabrina Chan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>sabrina.chan@prenetics.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Media: </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Richard Barton +852 9301 2056 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Harry Florry +852 9818 2239</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nicolas Mo +852 6019 9877</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>prenetics-HKG@finsbury.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;<IMG SRC="tm2127588d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains forward-looking statements
within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act that are based on beliefs and assumptions
and on information currently available to Artisan and Prenetics and also contains certain financial forecasts and projections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All statements other than statements of historical
fact contained in this press release, including, but not limited to, statements as to future results of operations and financial position,
Prenetics&rsquo; plans for new product development and geographic expansion, objectives of management for future operations of Prenetics,
projections of market opportunity and revenue growth, competitive position, technological and market trends, anticipated benefits of the
transaction and expectations related to the terms of the transaction, are also forward-looking statements. In some cases, you can identify
forward-looking statements by the following words: &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo;
 &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo;
 &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo; &ldquo;ongoing,&rdquo; &ldquo;target,&rdquo;
 &ldquo;seek&rdquo; or the negative or plural of these words, or other similar expressions that are predictions or indicate future events
or prospects, although not all forward-looking statements contain these words. These statements are based upon estimates and forecasts
and reflect the views, assumptions, expectations, and opinions of Artisan and Prenetics, which involve risks, uncertainties and other
factors that may cause actual results, levels of activity, performance or achievements to be materially different from those expressed
or implied by these forward-looking statements. Any such estimates, assumptions, expectations, forecasts, views or opinions, whether or
not identified in this press release, should be regarded as indicative, preliminary and for illustrative purposes only and should not
be relied upon as being necessarily indicative of future results. Although each of Artisan, Prenetics and PubCo believes that it has a
reasonable basis for each forward-looking statement contained in this press release, each of Artisan, Prenetics and PubCo caution you
that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently
uncertain. You should carefully consider the foregoing factors and the other risks and uncertainties described in the &ldquo;Risk Factors&rdquo;
section of PubCo&rsquo;s registration statement on Form F-4, the proxy statement/ prospectus therein, and other documents filed by Artisan
or PubCo from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause
actual events and results to differ materially from those expressed or implied in the forward-looking statements. Neither Artisan, Prenetics
nor PubCo can assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements
are subject to a number of risks and uncertainties, including the ability to complete the business combination due to the failure to satisfy
other closing conditions in the business combination agreement, the occurrence of any event that could give rise to the termination of
the business combination agreement, the ability to recognize the anticipated benefits of the business combination, costs related to the
transaction, the impact of the global COVID-19 pandemic, the risk that the transaction disrupts current plans and operations as a result
of the announcement and consummation of the transaction, the outcome of any potential litigation, government or regulatory proceedings
and other risks and uncertainties, including those included under the heading &ldquo;Risk Factors&rdquo; in the registration statement
on Form F-4 filed by PubCo with the SEC and those included under the heading &ldquo;Risk Factors&rdquo; in the final prospectus of Artisan
dated May 13, 2021 and in its subsequent quarterly reports on Form 10-Q and other filings with the SEC. In light of the significant uncertainties
in these forward-looking statements, you should not regard these statements as a representation or warranty by Artisan, Prenetics, PubCo,
their respective directors, officers or employees or any other person that Artisan, Prenetics or PubCo will achieve their objectives and
plans in any specified time frame, or at all. The forward-looking statements in this press release represent the views of Artisan, Prenetics
and PubCo as of the date of this press release. Subsequent events and developments may cause those views to change. However, while Artisan,
Prenetics and PubCo may update these forward-looking statements in the future, Artisan, Prenetics and PubCo specifically disclaim any
obligation to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements
as representing the views of Artisan, Prenetics or PubCo as of any date subsequent to the date of this press release. Accordingly, undue
reliance should not be placed upon the forward-looking statements.</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B>A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c6b3d61f-3426-48e5-bd90-26eaf66925d1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2127588d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127588d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  O * # 2(  A$! Q$!_\0
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CP.W;-7[*R2PMT@BDD:.-%10[9P ,?G0!9HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2127588d1_ex99-1img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2127588d1_ex99-1img003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "7 .(# 2(  A$! Q$!_\0
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M:YA5# Y'&1EAV'TK?\0ZRMZ(8["[OOLOD)&\,HV*2H S@$@YQFFB6W>R*_\
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M,C/3':HF6INU1M2 A*\5&P]JFX[_ *5&V2: (W<#&Q=I'>J[9)R>34K=:8:
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MA.<=Z!&F]L'EL;MQ/2G+M8 ;C& <8&#G_P"M57%<41\]#3@H8Y'.*4L!_ 2
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M<D#&35S2U+7Z_P"R":)-1BVA;F]WKY\^)EU_:'CZ]53E8 D ]MJY/ZDU]"<
MY/05\S:VTY\2:E+>QM%</.\C(PY 8DCZC&*G KWI2\BZCV1G%1R.F/:JL[ C
M%77<%1@$@]ZS95W29!/TKNL2F,A&&JRP-5>5^M2PS;N&!!]Z315Q2OJ*A>%6
MY_G5MAGTJ%A4CN4I+=<9Z53DCVG@UJLO'-4YX2>12&5.?2BCGT-%.PRV$(D.
MW&XC@D$\>YIP;";UE1N?X5R6'I2R1B,K#@G&"51<_KTJ3[#C$JE W5< <?A_
MC19]"+DB+YR#<GX,*?Y<<*$XVJ#D[<_TJ(M,D?!7>W"J0/SJS9>9)<QQW(1
MV<*IR[8&?H/Z4[HEE=Q\ZR.CNN,9. !^%3D 0E WWA\H3@D?Y[U&\,L);[/*
MSNP)$FYB0?0$<=.*;ILD313S@.\N.F2Q4=ER:E.TK/J#VN*TA4.T:*A'RX<\
M#UZ>U3), K?O VT9\SH#Z_3%.L8Y+J_CQLA$@PYD' ;IDD]![5=O-,2+9;RW
MB743<M(#CG/3'%4FWL0S<\(^=I8&JW1CC2Z!@MKPS+&44G#N@Y+,.G3UQFO6
M/!&H3S17SW4OGNT@VE(MH( P"6."Q]21G]*P?#++_P (MIRI@Q+%A 5X')Z9
MK5MY&MF<PGRS(<ML&,GI7)4@Y^HU=.YT=]J!>VNHY[5HDC *R%P0W/&/>LEF
MCD.(WW$#)QV%5YY6N;9HIV\V)N&1QD'\*JNQMH0(6V*!@!?2E2@XZ7'?N.O-
M1%D\2+#))/,2L46,%SC./;@'DTZSO+B6X=+FT-LH4%6=P=Q[@?3UJNL\THR7
M8NO*GT]:1KF1<?OMW?.*U:;>XN9=C5AO[*;(%RA*]:LL\*@%G !Z9'6LN*X,
MA+'&3U.*E\YQD[NO6H:&GW-!=C ]1SW&*NZ8RQW,GRLQV=A[UA?:).SFE6\G
M0_+*P^E3*/,K#OJ=;+<(UJ[*'.5.-HY_"O-_%^GZ9XA5HY(;FPU"WB\R*]N+
M<I$%_NN_3'X\?H=[^T+OIY[XJM<WKF-DD;>C#!5@""/I4TH.#NA2?,>'WHNK
M&>6VO+=HIXVVNOIZ'Z'UJB"78?*1D9SU%=?XZG-WK\6YCG[. #CMDUS#6S*$
M9YONCDXQSZFO2BFU<A,BV%5&1O/MQ4$J G&6 SV.*ED0PQ%W9V(Y;;DY^@JM
M(\B,<0,5Z\8S^%#5EJ6F68W(7 ;/IG_&FNS(AV1_-W '7Z54/F,"5V[3_>'\
MQ5V!P$ 9@<#&16;C<JXTNI )X)[-P:B?I4[A6XZ_A43 8ZTK#*1 R:*GVC^Z
M/RHH'<!%).P3[4T"[0<JFXD_Y^E1S_9T@4EIS &*J-V-_N?2BBLZONQ<OZZ"
M6K+JLDGEV\)96;Y0H SC&>I]J:-/DAN4<1)-S@J[<*/7W-%%:02J?$3+0TI)
M9I=MK"46-L@G:,@].*J:JUI92+]D*+L(B<;#][&3@^G6BBEB/=BVA0=W8O1F
MR,"0[1).XW[G+;1[DC!Q[ 59NK9& MVFBEN I83;"%!R,'!&<<CWXHHHC4;D
MD'+I<T;'X@G0;&'3)=):Y^RQ@&:&4(K#) .TC(J_)\3T@MFN'T6;RPN[<MPO
M3Z8HHK&U[Z]+E\J+>H?$+^S=3&G3Z0[SX&UHYP%?(!SR..HZU4G^):"0PMHL
M^X -@7"]#^%%%*BG))M]A.*O8ST^+=FCM_Q*;D;!D_OEX_2K,WQ+M4@\]](N
M5C X!G4GGZ"BBE"4I<S;V&X*Q)#\3( 0?['N@IQC,R=ZM-\4K6*$M)HEX/FQ
MQ-&:**T<+QO<5D.3XFVDB*XT>[ 89_UJ4T?$^R\TQ#2KOS ,E?,3I112<+):
MBL$WQ2L88]\FDW@4=3YB?XUGS?$^RG(*Z;>!,9^^G^-%%%N65D%KF%J&OQ>(
M+R*[@@DAC1/+^<@DG/M]:JM+'-*\.-Q3!;(XYHHKIIS=H^8G%!(O'055D5=X
M<HJMC&5SS^'2BBMY),A$3K]X'IBHHT\L_*3MP!M)SBBBLY)7N6B<'C&,4QZ*
-*R92(BPSTHHHI#/_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
